aluates Reports

$ 0.0

Automative

Global Therapeutic Monoclonal Antibodies Market Research Report 2025

Published Date: May 2025

Report Code: QYRE-Auto-17F16367

Global Therapeutic Monoclonal Antibodies Market Research Report 2023

BUY CHAPTERS

Global Therapeutic Monoclonal Antibodies Market Research Report 2025

Code: QYRE-Auto-17F16367

Report

May 2025

Pages:99

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

AbbVie

Johnson & Johnson

Novartis

Gilead Sciences

Roche

Bristol–Myers Squibb

Amgen Inc

Astrazeneca plc

Merck

Takeda

Merck KGaA

Seagen

Eli Lilly

Ono Pharmaceutical

Pfizer Inc

Regeneron

Innovent

Hengrui Medicine

Therapeutic Monoclonal Antibodies Market Size

The global market for Therapeutic Monoclonal Antibodies was valued at US$ 196300 million in the year 2024 and is projected to reach a revised size of US$ 403510 million by 2031, growing at a CAGR of 11.0% during the forecast period.

Therapeutic Monoclonal Antibodies Market

Monoclonal antibodies (MABs) are a type of targeted drug therapy. These drugs recognise and find specific proteins on cancer cells. There are many different MABs to treat cancer. They work in different ways to kill the cancer cell or stop it from growing.

The Therapeutic Antibodies Drug Market is driven by the remarkable potential of therapeutic antibodies to treat a diverse array of diseases, from cancer and autoimmune disorders to infectious diseases. Monoclonal antibodies have gained prominence as highly targeted and effective therapeutic agents that can modulate the immune system, neutralize pathogens, and inhibit disease-associated proteins. As precision medicine and biopharmaceutical innovations continue to advance, the demand for therapeutic antibodies grows. Innovations in antibody design, engineering, and manufacturing technologies further contribute to market expansion. Nevertheless, a significant challenge for this market is the need to address high production costs, optimize therapeutic antibody development processes, and navigate complex regulatory pathways while ensuring accessibility and affordability for patients. Overcoming manufacturing complexities, managing research and development costs, and addressing regulatory standards are ongoing challenges. Additionally, the market faces competition from small molecules and other biologic therapies, necessitating continuous research and development efforts to unlock the full therapeutic potential of therapeutic antibodies. Striking a balance between providing safe, effective, and accessible therapeutic antibody drugs while addressing scientific and regulatory challenges is essential for the continued growth of the Therapeutic Antibodies Drug Market.

This report aims to provide a comprehensive presentation of the global market for Therapeutic Monoclonal Antibodies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Therapeutic Monoclonal Antibodies.

The Therapeutic Monoclonal Antibodies market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Therapeutic Monoclonal Antibodies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Therapeutic Monoclonal Antibodies companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Therapeutic Monoclonal Antibodies Market Report

Report Metric	Details
Report Name	Therapeutic Monoclonal Antibodies Market
Accounted market size in year	US$ 196300 million
Forecasted market size in 2031	US$ 403510 million
CAGR	11.0%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Mouse-derived Antibodies Chimeric Antibodies Humanized Antibodies
Segment by Application	Immune Diseases Cancer Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	AbbVie, Johnson & Johnson, Novartis, Gilead Sciences, Roche, Bristol-Myers Squibb, Amgen, AstraZeneca, Merck & Co, Takeda, Merck KGaA, Seagen, Eli Lilly, Ono Pharmaceutical, Pfizer, Regeneron, Innovent, Hengrui Medicine
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Therapeutic Monoclonal Antibodies company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Therapeutic Monoclonal Antibodies Market growing?

Ans: The Therapeutic Monoclonal Antibodies Market witnessing a CAGR of 11.0% during the forecast period 2025-2031.

What is the Therapeutic Monoclonal Antibodies Market size in 2031?

Ans: The Therapeutic Monoclonal Antibodies Market size in 2031 will be US$ 403510 million.

Who are the main players in the Therapeutic Monoclonal Antibodies Market report?

Ans: The main players in the Therapeutic Monoclonal Antibodies Market are AbbVie, Johnson & Johnson, Novartis, Gilead Sciences, Roche, Bristol-Myers Squibb, Amgen, AstraZeneca, Merck & Co, Takeda, Merck KGaA, Seagen, Eli Lilly, Ono Pharmaceutical, Pfizer, Regeneron, Innovent, Hengrui Medicine

What are the Application segmentation covered in the Therapeutic Monoclonal Antibodies Market report?

Ans: The Applications covered in the Therapeutic Monoclonal Antibodies Market report are Immune Diseases, Cancer, Other

What are the Type segmentation covered in the Therapeutic Monoclonal Antibodies Market report?

Ans: The Types covered in the Therapeutic Monoclonal Antibodies Market report are Mouse-derived Antibodies, Chimeric Antibodies, Humanized Antibodies

Recommended Reports

Monoclonal Antibody Markets

Antibody Drug Conjugates

Cancer Therapeutics

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Therapeutic Monoclonal Antibodies Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Mouse-derived Antibodies

1.2.3 Chimeric Antibodies

1.2.4 Humanized Antibodies

1.3 Market by Application

1.3.1 Global Therapeutic Monoclonal Antibodies Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Immune Diseases

1.3.3 Cancer

1.3.4 Other

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Therapeutic Monoclonal Antibodies Market Perspective (2020-2031)

2.2 Global Therapeutic Monoclonal Antibodies Growth Trends by Region

2.2.1 Global Therapeutic Monoclonal Antibodies Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Therapeutic Monoclonal Antibodies Historic Market Size by Region (2020-2025)

2.2.3 Therapeutic Monoclonal Antibodies Forecasted Market Size by Region (2026-2031)

2.3 Therapeutic Monoclonal Antibodies Market Dynamics

2.3.1 Therapeutic Monoclonal Antibodies Industry Trends

2.3.2 Therapeutic Monoclonal Antibodies Market Drivers

2.3.3 Therapeutic Monoclonal Antibodies Market Challenges

2.3.4 Therapeutic Monoclonal Antibodies Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Therapeutic Monoclonal Antibodies Players by Revenue

3.1.1 Global Top Therapeutic Monoclonal Antibodies Players by Revenue (2020-2025)

3.1.2 Global Therapeutic Monoclonal Antibodies Revenue Market Share by Players (2020-2025)

3.2 Global Therapeutic Monoclonal Antibodies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Therapeutic Monoclonal Antibodies Revenue

3.4 Global Therapeutic Monoclonal Antibodies Market Concentration Ratio

3.4.1 Global Therapeutic Monoclonal Antibodies Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Therapeutic Monoclonal Antibodies Revenue in 2024

3.5 Global Key Players of Therapeutic Monoclonal Antibodies Head office and Area Served

3.6 Global Key Players of Therapeutic Monoclonal Antibodies, Product and Application

3.7 Global Key Players of Therapeutic Monoclonal Antibodies, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Therapeutic Monoclonal Antibodies Breakdown Data by Type

4.1 Global Therapeutic Monoclonal Antibodies Historic Market Size by Type (2020-2025)

4.2 Global Therapeutic Monoclonal Antibodies Forecasted Market Size by Type (2026-2031)

5 Therapeutic Monoclonal Antibodies Breakdown Data by Application

5.1 Global Therapeutic Monoclonal Antibodies Historic Market Size by Application (2020-2025)

5.2 Global Therapeutic Monoclonal Antibodies Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Therapeutic Monoclonal Antibodies Market Size (2020-2031)

6.2 North America Therapeutic Monoclonal Antibodies Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Therapeutic Monoclonal Antibodies Market Size by Country (2020-2025)

6.4 North America Therapeutic Monoclonal Antibodies Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Therapeutic Monoclonal Antibodies Market Size (2020-2031)

7.2 Europe Therapeutic Monoclonal Antibodies Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Therapeutic Monoclonal Antibodies Market Size by Country (2020-2025)

7.4 Europe Therapeutic Monoclonal Antibodies Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Therapeutic Monoclonal Antibodies Market Size (2020-2031)

8.2 Asia-Pacific Therapeutic Monoclonal Antibodies Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Therapeutic Monoclonal Antibodies Market Size by Region (2020-2025)

8.4 Asia-Pacific Therapeutic Monoclonal Antibodies Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Therapeutic Monoclonal Antibodies Market Size (2020-2031)

9.2 Latin America Therapeutic Monoclonal Antibodies Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Therapeutic Monoclonal Antibodies Market Size by Country (2020-2025)

9.4 Latin America Therapeutic Monoclonal Antibodies Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Therapeutic Monoclonal Antibodies Market Size (2020-2031)

10.2 Middle East & Africa Therapeutic Monoclonal Antibodies Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Therapeutic Monoclonal Antibodies Market Size by Country (2020-2025)

10.4 Middle East & Africa Therapeutic Monoclonal Antibodies Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 AbbVie

11.1.1 AbbVie Company Details

11.1.2 AbbVie Business Overview

11.1.3 AbbVie Therapeutic Monoclonal Antibodies Introduction

11.1.4 AbbVie Revenue in Therapeutic Monoclonal Antibodies Business (2020-2025)

11.1.5 AbbVie Recent Development

11.2 Johnson & Johnson

11.2.1 Johnson & Johnson Company Details

11.2.2 Johnson & Johnson Business Overview

11.2.3 Johnson & Johnson Therapeutic Monoclonal Antibodies Introduction

11.2.4 Johnson & Johnson Revenue in Therapeutic Monoclonal Antibodies Business (2020-2025)

11.2.5 Johnson & Johnson Recent Development

11.3 Novartis

11.3.1 Novartis Company Details

11.3.2 Novartis Business Overview

11.3.3 Novartis Therapeutic Monoclonal Antibodies Introduction

11.3.4 Novartis Revenue in Therapeutic Monoclonal Antibodies Business (2020-2025)

11.3.5 Novartis Recent Development

11.4 Gilead Sciences

11.4.1 Gilead Sciences Company Details

11.4.2 Gilead Sciences Business Overview

11.4.3 Gilead Sciences Therapeutic Monoclonal Antibodies Introduction

11.4.4 Gilead Sciences Revenue in Therapeutic Monoclonal Antibodies Business (2020-2025)

11.4.5 Gilead Sciences Recent Development

11.5 Roche

11.5.1 Roche Company Details

11.5.2 Roche Business Overview

11.5.3 Roche Therapeutic Monoclonal Antibodies Introduction

11.5.4 Roche Revenue in Therapeutic Monoclonal Antibodies Business (2020-2025)

11.5.5 Roche Recent Development

11.6 Bristol-Myers Squibb

11.6.1 Bristol-Myers Squibb Company Details

11.6.2 Bristol-Myers Squibb Business Overview

11.6.3 Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Introduction

11.6.4 Bristol-Myers Squibb Revenue in Therapeutic Monoclonal Antibodies Business (2020-2025)

11.6.5 Bristol-Myers Squibb Recent Development

11.7 Amgen

11.7.1 Amgen Company Details

11.7.2 Amgen Business Overview

11.7.3 Amgen Therapeutic Monoclonal Antibodies Introduction

11.7.4 Amgen Revenue in Therapeutic Monoclonal Antibodies Business (2020-2025)

11.7.5 Amgen Recent Development

11.8 AstraZeneca

11.8.1 AstraZeneca Company Details

11.8.2 AstraZeneca Business Overview

11.8.3 AstraZeneca Therapeutic Monoclonal Antibodies Introduction

11.8.4 AstraZeneca Revenue in Therapeutic Monoclonal Antibodies Business (2020-2025)

11.8.5 AstraZeneca Recent Development

11.9 Merck & Co

11.9.1 Merck & Co Company Details

11.9.2 Merck & Co Business Overview

11.9.3 Merck & Co Therapeutic Monoclonal Antibodies Introduction

11.9.4 Merck & Co Revenue in Therapeutic Monoclonal Antibodies Business (2020-2025)

11.9.5 Merck & Co Recent Development

11.10 Takeda

11.10.1 Takeda Company Details

11.10.2 Takeda Business Overview

11.10.3 Takeda Therapeutic Monoclonal Antibodies Introduction

11.10.4 Takeda Revenue in Therapeutic Monoclonal Antibodies Business (2020-2025)

11.10.5 Takeda Recent Development

11.11 Merck KGaA

11.11.1 Merck KGaA Company Details

11.11.2 Merck KGaA Business Overview

11.11.3 Merck KGaA Therapeutic Monoclonal Antibodies Introduction

11.11.4 Merck KGaA Revenue in Therapeutic Monoclonal Antibodies Business (2020-2025)

11.11.5 Merck KGaA Recent Development

11.12 Seagen

11.12.1 Seagen Company Details

11.12.2 Seagen Business Overview

11.12.3 Seagen Therapeutic Monoclonal Antibodies Introduction

11.12.4 Seagen Revenue in Therapeutic Monoclonal Antibodies Business (2020-2025)

11.12.5 Seagen Recent Development

11.13 Eli Lilly

11.13.1 Eli Lilly Company Details

11.13.2 Eli Lilly Business Overview

11.13.3 Eli Lilly Therapeutic Monoclonal Antibodies Introduction

11.13.4 Eli Lilly Revenue in Therapeutic Monoclonal Antibodies Business (2020-2025)

11.13.5 Eli Lilly Recent Development

11.14 Ono Pharmaceutical

11.14.1 Ono Pharmaceutical Company Details

11.14.2 Ono Pharmaceutical Business Overview

11.14.3 Ono Pharmaceutical Therapeutic Monoclonal Antibodies Introduction

11.14.4 Ono Pharmaceutical Revenue in Therapeutic Monoclonal Antibodies Business (2020-2025)

11.14.5 Ono Pharmaceutical Recent Development

11.15 Pfizer

11.15.1 Pfizer Company Details

11.15.2 Pfizer Business Overview

11.15.3 Pfizer Therapeutic Monoclonal Antibodies Introduction

11.15.4 Pfizer Revenue in Therapeutic Monoclonal Antibodies Business (2020-2025)

11.15.5 Pfizer Recent Development

11.16 Regeneron

11.16.1 Regeneron Company Details

11.16.2 Regeneron Business Overview

11.16.3 Regeneron Therapeutic Monoclonal Antibodies Introduction

11.16.4 Regeneron Revenue in Therapeutic Monoclonal Antibodies Business (2020-2025)

11.16.5 Regeneron Recent Development

11.17 Innovent

11.17.1 Innovent Company Details

11.17.2 Innovent Business Overview

11.17.3 Innovent Therapeutic Monoclonal Antibodies Introduction

11.17.4 Innovent Revenue in Therapeutic Monoclonal Antibodies Business (2020-2025)

11.17.5 Innovent Recent Development

11.18 Hengrui Medicine

11.18.1 Hengrui Medicine Company Details

11.18.2 Hengrui Medicine Business Overview

11.18.3 Hengrui Medicine Therapeutic Monoclonal Antibodies Introduction

11.18.4 Hengrui Medicine Revenue in Therapeutic Monoclonal Antibodies Business (2020-2025)

11.18.5 Hengrui Medicine Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

AbbVie

Johnson & Johnson

Novartis

Gilead Sciences

Roche

Bristol–Myers Squibb

Amgen Inc

Astrazeneca plc

Merck

Takeda

Merck KGaA

Seagen

Eli Lilly

Ono Pharmaceutical

Pfizer Inc

Regeneron

Innovent

Hengrui Medicine

List of Tables

Table 1. Global Therapeutic Monoclonal Antibodies Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Mouse-derived Antibodies

Table 3. Key Players of Chimeric Antibodies

Table 4. Key Players of Humanized Antibodies

Table 5. Global Therapeutic Monoclonal Antibodies Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Therapeutic Monoclonal Antibodies Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Therapeutic Monoclonal Antibodies Market Size by Region (2020-2025) & (US$ Million)

Table 8. Global Therapeutic Monoclonal Antibodies Market Share by Region (2020-2025)

Table 9. Global Therapeutic Monoclonal Antibodies Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 10. Global Therapeutic Monoclonal Antibodies Market Share by Region (2026-2031)

Table 11. Therapeutic Monoclonal Antibodies Market Trends

Table 12. Therapeutic Monoclonal Antibodies Market Drivers

Table 13. Therapeutic Monoclonal Antibodies Market Challenges

Table 14. Therapeutic Monoclonal Antibodies Market Restraints

Table 15. Global Therapeutic Monoclonal Antibodies Revenue by Players (2020-2025) & (US$ Million)

Table 16. Global Therapeutic Monoclonal Antibodies Market Share by Players (2020-2025)

Table 17. Global Top Therapeutic Monoclonal Antibodies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Therapeutic Monoclonal Antibodies as of 2024)

Table 18. Ranking of Global Top Therapeutic Monoclonal Antibodies Companies by Revenue (US$ Million) in 2024

Table 19. Global 5 Largest Players Market Share by Therapeutic Monoclonal Antibodies Revenue (CR5 and HHI) & (2020-2025)

Table 20. Global Key Players of Therapeutic Monoclonal Antibodies, Headquarters and Area Served

Table 21. Global Key Players of Therapeutic Monoclonal Antibodies, Product and Application

Table 22. Global Key Players of Therapeutic Monoclonal Antibodies, Date of Enter into This Industry

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Therapeutic Monoclonal Antibodies Market Size by Type (2020-2025) & (US$ Million)

Table 25. Global Therapeutic Monoclonal Antibodies Revenue Market Share by Type (2020-2025)

Table 26. Global Therapeutic Monoclonal Antibodies Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 27. Global Therapeutic Monoclonal Antibodies Revenue Market Share by Type (2026-2031)

Table 28. Global Therapeutic Monoclonal Antibodies Market Size by Application (2020-2025) & (US$ Million)

Table 29. Global Therapeutic Monoclonal Antibodies Revenue Market Share by Application (2020-2025)

Table 30. Global Therapeutic Monoclonal Antibodies Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 31. Global Therapeutic Monoclonal Antibodies Revenue Market Share by Application (2026-2031)

Table 32. North America Therapeutic Monoclonal Antibodies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 33. North America Therapeutic Monoclonal Antibodies Market Size by Country (2020-2025) & (US$ Million)

Table 34. North America Therapeutic Monoclonal Antibodies Market Size by Country (2026-2031) & (US$ Million)

Table 35. Europe Therapeutic Monoclonal Antibodies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 36. Europe Therapeutic Monoclonal Antibodies Market Size by Country (2020-2025) & (US$ Million)

Table 37. Europe Therapeutic Monoclonal Antibodies Market Size by Country (2026-2031) & (US$ Million)

Table 38. Asia-Pacific Therapeutic Monoclonal Antibodies Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 39. Asia-Pacific Therapeutic Monoclonal Antibodies Market Size by Region (2020-2025) & (US$ Million)

Table 40. Asia-Pacific Therapeutic Monoclonal Antibodies Market Size by Region (2026-2031) & (US$ Million)

Table 41. Latin America Therapeutic Monoclonal Antibodies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 42. Latin America Therapeutic Monoclonal Antibodies Market Size by Country (2020-2025) & (US$ Million)

Table 43. Latin America Therapeutic Monoclonal Antibodies Market Size by Country (2026-2031) & (US$ Million)

Table 44. Middle East & Africa Therapeutic Monoclonal Antibodies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 45. Middle East & Africa Therapeutic Monoclonal Antibodies Market Size by Country (2020-2025) & (US$ Million)

Table 46. Middle East & Africa Therapeutic Monoclonal Antibodies Market Size by Country (2026-2031) & (US$ Million)

Table 47. AbbVie Company Details

Table 48. AbbVie Business Overview

Table 49. AbbVie Therapeutic Monoclonal Antibodies Product

Table 50. AbbVie Revenue in Therapeutic Monoclonal Antibodies Business (2020-2025) & (US$ Million)

Table 51. AbbVie Recent Development

Table 52. Johnson & Johnson Company Details

Table 53. Johnson & Johnson Business Overview

Table 54. Johnson & Johnson Therapeutic Monoclonal Antibodies Product

Table 55. Johnson & Johnson Revenue in Therapeutic Monoclonal Antibodies Business (2020-2025) & (US$ Million)

Table 56. Johnson & Johnson Recent Development

Table 57. Novartis Company Details

Table 58. Novartis Business Overview

Table 59. Novartis Therapeutic Monoclonal Antibodies Product

Table 60. Novartis Revenue in Therapeutic Monoclonal Antibodies Business (2020-2025) & (US$ Million)

Table 61. Novartis Recent Development

Table 62. Gilead Sciences Company Details

Table 63. Gilead Sciences Business Overview

Table 64. Gilead Sciences Therapeutic Monoclonal Antibodies Product

Table 65. Gilead Sciences Revenue in Therapeutic Monoclonal Antibodies Business (2020-2025) & (US$ Million)

Table 66. Gilead Sciences Recent Development

Table 67. Roche Company Details

Table 68. Roche Business Overview

Table 69. Roche Therapeutic Monoclonal Antibodies Product

Table 70. Roche Revenue in Therapeutic Monoclonal Antibodies Business (2020-2025) & (US$ Million)

Table 71. Roche Recent Development

Table 72. Bristol-Myers Squibb Company Details

Table 73. Bristol-Myers Squibb Business Overview

Table 74. Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Product

Table 75. Bristol-Myers Squibb Revenue in Therapeutic Monoclonal Antibodies Business (2020-2025) & (US$ Million)

Table 76. Bristol-Myers Squibb Recent Development

Table 77. Amgen Company Details

Table 78. Amgen Business Overview

Table 79. Amgen Therapeutic Monoclonal Antibodies Product

Table 80. Amgen Revenue in Therapeutic Monoclonal Antibodies Business (2020-2025) & (US$ Million)

Table 81. Amgen Recent Development

Table 82. AstraZeneca Company Details

Table 83. AstraZeneca Business Overview

Table 84. AstraZeneca Therapeutic Monoclonal Antibodies Product

Table 85. AstraZeneca Revenue in Therapeutic Monoclonal Antibodies Business (2020-2025) & (US$ Million)

Table 86. AstraZeneca Recent Development

Table 87. Merck & Co Company Details

Table 88. Merck & Co Business Overview

Table 89. Merck & Co Therapeutic Monoclonal Antibodies Product

Table 90. Merck & Co Revenue in Therapeutic Monoclonal Antibodies Business (2020-2025) & (US$ Million)

Table 91. Merck & Co Recent Development

Table 92. Takeda Company Details

Table 93. Takeda Business Overview

Table 94. Takeda Therapeutic Monoclonal Antibodies Product

Table 95. Takeda Revenue in Therapeutic Monoclonal Antibodies Business (2020-2025) & (US$ Million)

Table 96. Takeda Recent Development

Table 97. Merck KGaA Company Details

Table 98. Merck KGaA Business Overview

Table 99. Merck KGaA Therapeutic Monoclonal Antibodies Product

Table 100. Merck KGaA Revenue in Therapeutic Monoclonal Antibodies Business (2020-2025) & (US$ Million)

Table 101. Merck KGaA Recent Development

Table 102. Seagen Company Details

Table 103. Seagen Business Overview

Table 104. Seagen Therapeutic Monoclonal Antibodies Product

Table 105. Seagen Revenue in Therapeutic Monoclonal Antibodies Business (2020-2025) & (US$ Million)

Table 106. Seagen Recent Development

Table 107. Eli Lilly Company Details

Table 108. Eli Lilly Business Overview

Table 109. Eli Lilly Therapeutic Monoclonal Antibodies Product

Table 110. Eli Lilly Revenue in Therapeutic Monoclonal Antibodies Business (2020-2025) & (US$ Million)

Table 111. Eli Lilly Recent Development

Table 112. Ono Pharmaceutical Company Details

Table 113. Ono Pharmaceutical Business Overview

Table 114. Ono Pharmaceutical Therapeutic Monoclonal Antibodies Product

Table 115. Ono Pharmaceutical Revenue in Therapeutic Monoclonal Antibodies Business (2020-2025) & (US$ Million)

Table 116. Ono Pharmaceutical Recent Development

Table 117. Pfizer Company Details

Table 118. Pfizer Business Overview

Table 119. Pfizer Therapeutic Monoclonal Antibodies Product

Table 120. Pfizer Revenue in Therapeutic Monoclonal Antibodies Business (2020-2025) & (US$ Million)

Table 121. Pfizer Recent Development

Table 122. Regeneron Company Details

Table 123. Regeneron Business Overview

Table 124. Regeneron Therapeutic Monoclonal Antibodies Product

Table 125. Regeneron Revenue in Therapeutic Monoclonal Antibodies Business (2020-2025) & (US$ Million)

Table 126. Regeneron Recent Development

Table 127. Innovent Company Details

Table 128. Innovent Business Overview

Table 129. Innovent Therapeutic Monoclonal Antibodies Product

Table 130. Innovent Revenue in Therapeutic Monoclonal Antibodies Business (2020-2025) & (US$ Million)

Table 131. Innovent Recent Development

Table 132. Hengrui Medicine Company Details

Table 133. Hengrui Medicine Business Overview

Table 134. Hengrui Medicine Therapeutic Monoclonal Antibodies Product

Table 135. Hengrui Medicine Revenue in Therapeutic Monoclonal Antibodies Business (2020-2025) & (US$ Million)

Table 136. Hengrui Medicine Recent Development

Table 137. Research Programs/Design for This Report

Table 138. Key Data Information from Secondary Sources

Table 139. Key Data Information from Primary Sources

Table 140. Authors List of This Report

List of Figures

Figure 1. Therapeutic Monoclonal Antibodies Picture

Figure 2. Global Therapeutic Monoclonal Antibodies Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Therapeutic Monoclonal Antibodies Market Share by Type: 2024 VS 2031

Figure 4. Mouse-derived Antibodies Features

Figure 5. Chimeric Antibodies Features

Figure 6. Humanized Antibodies Features

Figure 7. Global Therapeutic Monoclonal Antibodies Market Size by Application (2020-2031) & (US$ Million)

Figure 8. Global Therapeutic Monoclonal Antibodies Market Share by Application: 2024 VS 2031

Figure 9. Immune Diseases Case Studies

Figure 10. Cancer Case Studies

Figure 11. Other Case Studies

Figure 12. Therapeutic Monoclonal Antibodies Report Years Considered

Figure 13. Global Therapeutic Monoclonal Antibodies Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 14. Global Therapeutic Monoclonal Antibodies Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 15. Global Therapeutic Monoclonal Antibodies Market Share by Region: 2024 VS 2031

Figure 16. Global Therapeutic Monoclonal Antibodies Market Share by Players in 2024

Figure 17. Global Top Therapeutic Monoclonal Antibodies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Therapeutic Monoclonal Antibodies as of 2024)

Figure 18. The Top 10 and 5 Players Market Share by Therapeutic Monoclonal Antibodies Revenue in 2024

Figure 19. North America Therapeutic Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 20. North America Therapeutic Monoclonal Antibodies Market Share by Country (2020-2031)

Figure 21. United States Therapeutic Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Canada Therapeutic Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe Therapeutic Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Therapeutic Monoclonal Antibodies Market Share by Country (2020-2031)

Figure 25. Germany Therapeutic Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. France Therapeutic Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. U.K. Therapeutic Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Italy Therapeutic Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Russia Therapeutic Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Nordic Countries Therapeutic Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific Therapeutic Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Therapeutic Monoclonal Antibodies Market Share by Region (2020-2031)

Figure 33. China Therapeutic Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Japan Therapeutic Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. South Korea Therapeutic Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Southeast Asia Therapeutic Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. India Therapeutic Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Australia Therapeutic Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America Therapeutic Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Therapeutic Monoclonal Antibodies Market Share by Country (2020-2031)

Figure 41. Mexico Therapeutic Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Brazil Therapeutic Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa Therapeutic Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Therapeutic Monoclonal Antibodies Market Share by Country (2020-2031)

Figure 45. Turkey Therapeutic Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Saudi Arabia Therapeutic Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. UAE Therapeutic Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. AbbVie Revenue Growth Rate in Therapeutic Monoclonal Antibodies Business (2020-2025)

Figure 49. Johnson & Johnson Revenue Growth Rate in Therapeutic Monoclonal Antibodies Business (2020-2025)

Figure 50. Novartis Revenue Growth Rate in Therapeutic Monoclonal Antibodies Business (2020-2025)

Figure 51. Gilead Sciences Revenue Growth Rate in Therapeutic Monoclonal Antibodies Business (2020-2025)

Figure 52. Roche Revenue Growth Rate in Therapeutic Monoclonal Antibodies Business (2020-2025)

Figure 53. Bristol-Myers Squibb Revenue Growth Rate in Therapeutic Monoclonal Antibodies Business (2020-2025)

Figure 54. Amgen Revenue Growth Rate in Therapeutic Monoclonal Antibodies Business (2020-2025)

Figure 55. AstraZeneca Revenue Growth Rate in Therapeutic Monoclonal Antibodies Business (2020-2025)

Figure 56. Merck & Co Revenue Growth Rate in Therapeutic Monoclonal Antibodies Business (2020-2025)

Figure 57. Takeda Revenue Growth Rate in Therapeutic Monoclonal Antibodies Business (2020-2025)

Figure 58. Merck KGaA Revenue Growth Rate in Therapeutic Monoclonal Antibodies Business (2020-2025)

Figure 59. Seagen Revenue Growth Rate in Therapeutic Monoclonal Antibodies Business (2020-2025)

Figure 60. Eli Lilly Revenue Growth Rate in Therapeutic Monoclonal Antibodies Business (2020-2025)

Figure 61. Ono Pharmaceutical Revenue Growth Rate in Therapeutic Monoclonal Antibodies Business (2020-2025)

Figure 62. Pfizer Revenue Growth Rate in Therapeutic Monoclonal Antibodies Business (2020-2025)

Figure 63. Regeneron Revenue Growth Rate in Therapeutic Monoclonal Antibodies Business (2020-2025)

Figure 64. Innovent Revenue Growth Rate in Therapeutic Monoclonal Antibodies Business (2020-2025)

Figure 65. Hengrui Medicine Revenue Growth Rate in Therapeutic Monoclonal Antibodies Business (2020-2025)

Figure 66. Bottom-up and Top-down Approaches for This Report

Figure 67. Data Triangulation

Figure 68. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Monoclonal Antibody Drugs for Cancer Market Research Report 2024

Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Insights Forecast to 2030

Global Small Molecule Targeted Cancer Therapy Market Research Report 2025

Global Anti CD20 Monoclonal Antibodies Market Research Report 2024

Global Monoclonal Antibody for Gastric Cancer Market Research Report 2024

Global Conjugated Monoclonal Antibodies Market Research Report 2024

Global Arthritis Monoclonal Antibodies Market Research Report 2024

Global Antibody Based Therapeutics Market Research Report 2024

Global Therapeutic Antibodies Drug Market Research Report 2024

Monoclonal Antibody Medicine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Monoclonal Antibodies Product Market Research Report 2024

Global Next Generation Monoclonal Antibodies Market Research Report 2024

Biologics Monoclonal Antibodies Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Hepatocellular Carcinoma Monoclonal Antibody Market Research Report 2025

Global Combination Antibody Therapy Market Research Report 2024

Global Anti CD25 Monoclonal Antibody Market Research Report 2024

Global Immunoglobulin G Antibody Therapeutics Market Insights Forecast to 2030

Antibody Therapeutics and Blood Antibody Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Monoclonal Antibodies for Non small Cell Lung Cancer Market Research Report 2025

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions